In this issue:
Estimation of the carrier frequency of FH alterations and implications for kidney cancer risk
Impact of pathologic lymph node-positive RCC on survival in patients without metastasis
Phase Ib/II trial of lenvatinib + pembrolizumab in advanced RCC, endometrial cancer, and other selected advanced solid tumours
Rates and predictors of perioperative complications in CN
Clinical and molecular features in hereditary leiomyomatosis and RCC
Diagnostic performance of contrastenhanced- ultrasound vs CT and MRI for renal masses
Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer
Histotype predicts the rate of lymph node invasion at nephrectomy in nonmetastatic RCC
Identification of low-dose multidrug combinations for sunitinib-naïve and pre-treated RCC
Salvage ipilimumab + nivolumab in patients with metastatic RCC after anti-PD-1
Please login below to download this issue (PDF)